Preparing for the Next Leap Forward in Multimodal Management of Esophageal/GEJ Cancer: An Interdisciplinary Tumor Board on Adjuvant Immunotherapy

Course Description

Esophageal cancer has a poor prognosis with 5-year survival rates below 35% in the non-metastatic setting. Despite the use of trimodality approaches with chemotherapy, radiation, and surgery, survival benefits remain suboptimal. Promisingly, recent phase 3 evidence suggests that adjuvant immunotherapy can significantly improve disease-free survival in patients with esophageal or gastroesophageal junction (GEJ) cancer. Moreover, a number of other trials are underway studying approaches that harness the patient’s own immune system with immunotherapy in different settings of locally advanced and earlier stage, indicating the expanding role of immunotherapy in the therapeutic management of esophageal or GEJ cancer. Preparing for new treatment strategies that can improve patient outcomes requires the cancer care team of radiation, medical, and surgical oncologists to work in a concerted multidisciplinary approach. This activity will provide a comprehensive and practically-oriented, multidisciplinary overview on the expanding role of immunotherapy in esophageal and GEJ cancer. Radiation and medical oncology experts will offer their insights to optimize the integration and use of immunotherapies in the multimodal management of esophageal and GEJ cancer.

Other Courses in this Series

Other Courses That May be of Interest